Analysis1994
Posted - 12 hours ago
$ELAB $QLGN Bull thesis for merger: Here are the synergies if they were to merge as one company.
1. Exosome Technology Integration with Therapeutics
Elevai Labs’ Exosome Technology: • Exosomes are extracellular vesicles capable of delivering proteins, lipids, and RNA to specific cells. Elevai specializes in leveraging this for regenerative skincare. • Technical strength: Their platform ensures targeted delivery with minimal immune activation and efficient cellular uptake. • Qualigen’s Therapeutic Pipeline: • Focuses on nucleolin-targeting therapeutics (e.g., QN-247) and G4-selective transcription inhibitors (e.g., QN-302) to disrupt tumor growth. • Challenge: Delivering these molecules to tumor sites while avoiding systemic toxicity. • Synergy: • Exosome-based drug delivery can encapsulate Qualigen’s nucleolin-targeting molecules, improving bioavailability and enabling more precise targeting of cancerous cells. • Example: Exosomes could be engineered to overexpress ligands for nucleolin receptors, enhancing tumor localization and therapeutic efficacy.
2. Diagnostics and Biomarker Targeting
Qualigen’s Diagnostic Expertise: • Their FastPack® platform provides real-time immunoassays for biomarkers. These systems are capable of detecting disease markers (e.g., cancer antigens) rapidly and accurately. • Exosome-Based Biomarker Detection: • Elevai’s exosomes could act as a diagnostic tool, where isolated patient-derived exosomes are analyzed for disease-specific RNA or proteins. • Integration: Qualigen’s FastPack® could incorporate Elevai’s expertise to develop diagnostic kits that leverage exosomal biomarkers, increasing sensitivity and specificity for diseases like cancer or metabolic disorders.
3. Enhanced Drug Pharmacokinetics
Current Issues in Oncology Drug Delivery: • Chemotherapeutic agents and inhibitors, like Qualigen’s QN-247, face challenges with short half-lives, systemic toxicity, and non-specific distribution. • Exosome Solutions: • Exosomes provide a natural, biocompatible nanocarrier for increasing the half-life of drugs in circulation. • For QN-247: • Encapsulation in exosomes would shield the drug from enzymatic degradation in the bloodstream. • Surface modifications (e.g., PEGylation) could further extend circulation time, enhancing accumulation at tumor sites.
4. Immunomodulation Applications
Cancer Therapy Challenges: • Immune evasion by tumors is a critical hurdle, requiring innovative approaches to modulate the tumor microenvironment. • Exosome-Based Immunotherapy: • Elevai’s exosome tech could potentially deliver immunostimulatory molecules (e.g., cytokines or siRNAs targeting immune checkpoints). • Qualigen’s focus on oncology could incorporate these immune-priming exosomes to synergistically enhance anti-tumor immune responses alongside QN-302 or QN-247.
5. Manufacturing and Scalability
Qualigen’s Therapeutic Manufacturing: • Currently relies on traditional small-molecule production pipelines. • Elevai’s Exosome Production: • Elevai likely uses a scalable bioreactor-based exosome production system optimized for clinical-grade applications. • Integration: • Qualigen could adopt Elevai’s scalable manufacturing platforms for incorporating exosomes into drug formulations. • This would reduce the development timeline for exosome-based delivery systems and diagnostics.
6. Expansion into Combination Therapies
Cancer therapies often benefit from combination approaches targeting multiple pathways. • QN-247 + Exosome Therapy: Deliver both nucleolin-targeting therapeutics and immunostimulatory payloads in a single exosome. • Exosome-Augmented Transcription Inhibitors: Encapsulating QN-302 in exosomes could improve tumor penetration and effectiveness in solid tumors.
ZippedCookie
Posted - 20 hours ago
$QLGN could get interesting now
RemyDaniels
Posted - 21 hours ago
$PHIO $QLGN LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?
Carl_K
Posted - 1 day ago
$QLGN So yesterday closed 40 cents above the conversion price. They were actually already funded a while ago, so from a financing perspective there was no need for an additional raise.
But there was the previous registration statement that should have been used by October 30, and the SEC obviously didn't approve it by then because we didn't see a filing of effectiveness before that date. Meaning the current financing actually gives execution to the previous prospectus. What was in the previous prospectus? Massive IR. Let's see some of that. Buckle up. Again: yesterday closed .40 cents above the conversion price. Meanwhile there are no shares left to short. And 8 days to cover if that takes into account the recent RSS.
Hallochen
Posted - 1 day ago
$QLGN $WKHS $SYRS $NCNC $TNXP
🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥
This is the private placement! This means that someone knows exactly what will happen soon. I suspect there will be good news soon! And we fly🚀🚀🚀
MoneyPennyStocks
Posted - 1 day ago
$QLGN dilution is sometimes used to let new investors in, did they mention if any of the dilution is for anything other than common a stock?
RageTrader
Posted - 1 day ago
$QLGN They just got done with a 50:1 reverse split, now bring on the dilution - which the market tends not to like and will bring the price down so it can be reverse split once again. You can tell that Bensler is on the scene because if there's one thing that he seems to excel at, it's dilute the hell out of stock. It's bad enough that QLGN was sliding down hill to begin with, now this. This is why most people just day trade this and similar crap. It's not suitable for a long term investment unless you have a high risk tolerance. In that case, just wait until it gets run back down and gamble from there.
Hallochen
Posted - 1 day ago
$QLGN $ADIL BUY BUY BUY 🚀🚀🚀💥💥💥💥💥🥳🥳🥳🥳🥳🥳🥳
wseamo1
Posted - 1 day ago
$QLGN congrats on a nice day!
Hallochen
Posted - 1 day ago
$QLGN $ADIL $PRFX $SOAR $NCNC
🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥
Hallochen
Posted - 1 day ago
$QLGN $ADIL $PRFX $SOAR $NCNC
🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥
panmax
Posted - 1 day ago
$QLGN something is cooking offering @marktprice
gary_bertier
Posted - 1 day ago
$QLGN #DISASTER 60% DILUTION BENDING US OVER
gary_bertier
Posted - 1 day ago
$QLGN NOTHING LIKE 60% DILUTION. #DISASTER
gary_bertier
Posted - 1 day ago
$QLGN 60% DILUTION HORRIBLE
gary_bertier
Posted - 1 day ago
@FidoucheiaryGainzzz $QLGN 50% DILUTION UGH
gary_bertier
Posted - 1 day ago
$QLGN MORE THAN 50% DILUTION GOING TO $2.00
gary_bertier
Posted - 1 day ago
$QLGN OVER 50% DILUTION WTF!!!
1Asianstockthoughts
Posted - 1 day ago
$QLGN hello traders of QlGN, there is a possibility of an up coming merger or acquisition of QLGN by ELAB CEO who was just put on QLGN board. Name is Graydon Bensler. Was the CFO and now CEO as of July of $ELAB now why would they add him to the board to look over there financial? Time will tell. But would keep eyes on both, ELAB is in a weird spot for a good jump if volume follows, expect good things from both in the next few weeks
wseamo1
Posted - 1 day ago
$QLGN No one listen to anything this trickster says: Hallochen He cannot, will not, and should not be trusted.
Hallochen
Posted - 1 day ago
$QLGN $ELAB The offering is expected to close on or about November 19, 2024, subject to satisfaction of customary closing conditions.🧐🧐🧐🧐🧐
🔥🔥🔥BE READY🔥🔥🔥
